



Resolution n°19-2021-e

Cost Extension for the D2EFT Project

Recalling Executive Board Resolution R15-2016-e, in which the Board approved the commitment of up to US\$8,806,936 for the Project entitled, “A randomised trial to compare dolutegravir + pharmacoenhanced darunavir versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first-line therapy: **D2EFT**’ (the “**Project**”), to be implemented by The University of New South Wales (“**UNSW**”) through the Kirby Institute for a four-year period;

Noting that the Project was extended by a further twelve months in February 2019, in order to include a third study arm, with no additional cost; and

Recalling Executive Board Resolution R5-2020-e, in which the Board approved funding to support measures for the global response to COVID-19, and in accordance with which an additional Output was added to the Project to assess the impact of COVID-19 in people living with HIV, clarify risks for people living with HIV, and inform outcomes with repurposed treatments for COVID-19 transmission risks, for total additional funding of US\$219,232, taking the total grant funding ceiling to US\$ 9,026,168;

Taking into account the assessment by the PRC, together with the Secretariat’s recommendations, the Board authorizes, subject to availability of funds, the Executive Director to commit additional funding of up to US\$1,292,984 for the Project and extend the duration of funding for the Project by a further twelve months.

The additional funding and the extension to the Project duration shall not apply to the new COVID-19 related Output approved through Resolution R5-2020-e and are conditional upon signature of formal amendment to the grant agreement for the Project.

Marisol Touraine
Chair of the Executive Board

Date: 14 September 2021